65 results
424B5
TCRX
Tscan Therapeutics Inc
17 Apr 24
Prospectus supplement for primary offering
9:58pm
and the impact on operating costs, liquidity and access to credit on any of the foregoing or other aspects of our business operations;
disruptions … such as (among others) the company’s ability to borrow funds and/or renew or roll over existing indebtedness and access to private capital sources
8-K
EX-1.1
TCRX
Tscan Therapeutics Inc
17 Apr 24
TScan Therapeutics Announces Launch of $125 million Proposed
6:25am
, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster … , unauthorized distribution, use, access, disablement, misappropriation or modification, or other compromise or misuse of or relating to any IT Systems
424B5
ze079knifwew01euplj
16 Apr 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
v9t425lec9fulhk4f4
7 Dec 23
TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations
7:15am
DEFA14A
sb03av blaqhj82f48y2
2 Jun 23
Additional proxy soliciting materials
4:05pm
8-K
EX-1.1
d85cr hao
31 May 23
TScan Therapeutics Announces Launch of Proposed Public Offering
8:16am
424B5
6oj0kxmr5zwyz5a
26 May 23
Prospectus supplement for primary offering
8:12pm
424B5
wmg0owrh7oixlt0m
25 May 23
Prospectus supplement for primary offering
4:59pm
8-K
EX-1.1
2vvxbyjo7 08kyoj
16 May 23
Other Events
5:21pm